<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01619020</url>
  </required_header>
  <id_info>
    <org_study_id>FHCRC IR 7532</org_study_id>
    <nct_id>NCT01619020</nct_id>
  </id_info>
  <brief_title>FlaxFx, A Research Study of the Effects of Flaxseed Lignans on Colon Health</brief_title>
  <acronym>FlaxFx</acronym>
  <official_title>Gut Microbiota and Colonic Gene Expression: A Lignan Trial in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas A&amp;M University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal (CRC) cancer is the third most common cancer in the United States and its&#xD;
      incidence is rising in younger populations. Diet seems to affect risk for CRC.&#xD;
&#xD;
      Many parts of our diet are processed and modified by the microbes or bacteria in our gut.&#xD;
      There are many different types of bacteria in our gut, each one of us has a &quot;community&quot; of&#xD;
      different types and amounts of each type.&#xD;
&#xD;
      When we eat flaxseeds, certain types of bacteria will process them - producing compounds that&#xD;
      can then affect our body. How much of these compounds are produced by each person depends on&#xD;
      the &quot;community&quot; of bacteria in the gut.&#xD;
&#xD;
      Flaxseed and in certain nuts contain lignans, compounds that may have health benefits. Gut&#xD;
      bacteria can convert the lignans into biologically active compounds that in animal models&#xD;
      prevent the development of colon cancer. The investigators will study how these biologically&#xD;
      active compounds affect colon cell-signaling pathways important to colorectal cancer risk.&#xD;
&#xD;
      Results from our study will bridge the current knowledge from animal studies and&#xD;
      epidemiologic studies and may help to inform approaches for future CRC prevention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 (Screening):&#xD;
&#xD;
      Potential participants submit a screening questionnaire for eligibility. Eligible&#xD;
      participants will come for an orientation for Part 1. If they consent the study coordinator&#xD;
      will measure their height and weight and give them all the materials to do the activities for&#xD;
      Part 1.&#xD;
&#xD;
        1. Stool sample&#xD;
&#xD;
        2. Days 1-3: take a lignan pill for three days&#xD;
&#xD;
        3. Day 3: 24-hour urine collection.&#xD;
&#xD;
      No all participants will be eligible for Part 2.&#xD;
&#xD;
      Part 2 (Trial):&#xD;
&#xD;
      Eligible participants will come for an orientation and consent.&#xD;
&#xD;
      Activities:&#xD;
&#xD;
        1. 3-day food record&#xD;
&#xD;
        2. Stool sample&#xD;
&#xD;
        3. Fasting blood draw.&#xD;
&#xD;
        4. Colon cleanse (at home). 2 months- no study activities Period 1,&#xD;
&#xD;
      1. Day 0: Stool sample 2. Day 0: 24-h urine collection 3. Take study capsule daily for 2&#xD;
      months. 4. Day 54: Stool sample 5. Day 54: 24-hour urine 6. Day 55: Fasting blood draw 7. Day&#xD;
      60 Sigmoidoscopy with biopsies 2 months- no study activities Period 2&#xD;
&#xD;
        1. Day 0: Stool sample&#xD;
&#xD;
        2. Day 0: 24-h urine collection&#xD;
&#xD;
        3. Take the other study capsule daily for 2 months.&#xD;
&#xD;
        4. Day 54: Stool sample&#xD;
&#xD;
        5. Day 54: 24-hour urine&#xD;
&#xD;
        6. Day 55: Fasting blood draw&#xD;
&#xD;
        7. Day 60 Sigmoidoscopy with biopsies&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mRNA expression in colonic mucosal tissue (stroma and epithelial) and exfoliated cells in individuals with low- or high-ENL excretion.</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Flaxseed Lignans</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flaxseed Lignans</intervention_name>
    <description>We will use a specially formulated dietary lignan supplement (Lignan Research Inc., San Diego, CA) as a source of lignans for the lignan challenge in the screening study and as a daily supplement in the intervention. It is a flaxseed extract that contains SDG (269 mg/g; 50 mg/capsule), pinoresinol diglucoside (160 mg/g), and lesser amounts of caffeic (50 mg/g), ferulic (40 mg/g) and coumaric acids (30 mg/g). Lignan capsules and placebo capsules will be prepared by Lignan Research, Inc., a well-established supplement company that follows GMP.</description>
    <arm_group_label>Flaxseed Lignans</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy&#xD;
&#xD;
          -  non-smoking men and women&#xD;
&#xD;
          -  ages 20-45 y&#xD;
&#xD;
          -  don't eat a lot of vegetables&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic medical illness, history of gastrointestinal disorders (e.g., ulcerative&#xD;
             colitis, Crohn disease, celiac sprue, HNPCC, familial adenomatous polyposis,&#xD;
             pancreatic disease, previous gastrointestinal resection, radiation or chemotherapy)&#xD;
             and cancer (other than non-melanoma skin cancer);&#xD;
&#xD;
          -  pregnancy or lactation;&#xD;
&#xD;
          -  weight change greater than 4.5 kg within past year;&#xD;
&#xD;
          -  oral or IV antibiotic use within the past 3 months;&#xD;
&#xD;
          -  alcohol intake of &gt;2 drinks/day (2 drinks being equivalent to 720 ml beer, 240 ml&#xD;
             wine, or 90 ml spirits);&#xD;
&#xD;
          -  dietary fiber intake &gt;15 g/day;&#xD;
&#xD;
          -  abnormal renal, liver or metabolic test results at baseline;&#xD;
&#xD;
          -  inability to swallow pills;&#xD;
&#xD;
          -  contraindications to sigmoidoscopy;&#xD;
&#xD;
          -  regular use of prescription or over-the-counter medications, including oral&#xD;
             contraceptives;&#xD;
&#xD;
          -  known allergy to nuts, seeds and flaxseed;&#xD;
&#xD;
          -  intention to relocate out of study area within next 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna Lampe, PhD Rd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FHCRC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>April 16, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2012</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Colon</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

